人間の20Sプロテアソームの阻害メカニズムにより,次世代の阻害剤の設計が可能である
Jil Schrader1, Fabian Henneberg1, Ricardo A Mata2
1Department of Structural Dynamics, Max Planck Institut für biophysikalische Chemie, Am Fassberg 11, D-37077 Göttingen, Germany.
まとめ
人間の20Sプロテアソムの高解像度構造とそのがん薬複合体は,抑制メカニズムに関する新しい洞察を明らかにしています. この知識は,がん治療のための次世代のプロテアソーム阻害剤の開発を導くことができます.
科学分野:
- 生物化学
- 構造生物学
- 薬剤化学
背景:
- プロテアソームは,がん治療における主要な標的であり,プロテアソーム阻害剤は,様々ながんの治療に臨床的に使用されます.
- タンパク質の構造と抑制メカニズムの理解は 効果的な抗がん剤の開発に不可欠です
研究 の 目的:
- ヒトの20Sプロテアソームとその抗癌阻害剤の複合体の高解像度結晶構造を決定する.
- プロテアソーム阻害の触媒的メカニズムについて 新しい洞察を得るために
主な方法:
- 構造を明らかにするためにX線結晶学を用いた.
- 1.8アングストームの解像度で本来のヒト20Sプロテアソムの構造を決定した.
- 解像度1. 9から2.1アングストームの6つの阻害タンパク質複合体の構造を解析した.
主要な成果:
- ヒト20Sプロテアソムの高解像度構造データを提供した.
- 臨床的に重要なタンパク質阻害剤の複合体に関する詳細な構造情報を明らかにした.
- 抑制の触媒的メカニズムとプロテアソムの活性部位に関する新しい洞察を提供した.
結論:
- この高解像度構造は プロテアソーム阻害メカニズムに関する理解を深めています
- 構造的な発見により,プロテアソーム活性部位の改訂された記述が必要である.
- この知識は次の世代の プロテアソームベースのがん治療薬の設計に役立つでしょう
さらに関連する動画
10:25Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
Published on: November 22, 2024
740
09:47Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates
Published on: May 10, 2022
3.2K
関連する概念動画
The Proteasome Structure
2.1K
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The proteasome is an...
2.1K
The Proteasome
1.9K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.9K
The Proteasome
10.4K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.4K
The Proteasome
5.0K
5.0K
The Electron Transport Chain
21.0K
The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
21.0K
Enzyme Inhibition
94.6K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
94.6K
